Guillain Barre syndrome; This serious case was reported by a consumer via sales rep and described the occurrence of guillain barre syndrome in a 71-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number X4EA5, expiry date 16-OCT-2025) for prophylaxis. On 19-DEC-2024, the patient received the 1st dose of Arexvy. On 30-DEC-2024, 11 days after receiving Arexvy, the patient experienced guillain barre syndrome (Verbatim: Guillain Barre syndrome) (serious criteria hospitalization and GSK medically significant). The patient was treated with immunoglobulins. The outcome of the guillain barre syndrome was not resolved. The reporter considered the guillain barre syndrome to be related to Arexvy. The company considered the guillain barre syndrome to be unrelated to Arexvy. Additional Information: GSK Receipt Date: 13-JAN-2025 The patient was in hospital for Guillain Barre syndrome and Guillain Barre syndrome was reported as worsened. Patient was vaccinated with Arexvy and went to emergency room on 31st December 2024. The patient had completed 5 treatments of IVIG and still in hospital. Patient was unable to walk and had no feeling/reflexes in legs, unable to move right arm/hand and could not feed herself and on thickened liquids due to swallowing issues.; Sender’s Comments: Guillain-Barre syndrome is an unlisted event which is considered unrelated to GSK vaccine Arexvy.